Journal of Clinical Oncology
Articles in this Issue
Statin exposure and clinical outcomes in metastatic prostate cancer: A propensity-matched TriNetX cohort study.
e17087 Background: Statins have pleiotropic biologic effects and have been hypothesized to favorably influence prostate ca...
Clinical outcomes of PD-1 versus PD-L1 inhibitors combined with chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A propensity score–matched study.
e20132 Background: Small cell lung cancer (SCLC) is a highly aggressive malignancy, with approximately two-thirds of patie...
Survival outcomes and subgroup efficacy analysis of Ga-68-NGUL and Lu-177-DGUL (pocuvotide satetraxetan) in patients with mCRPC: Results from a phase 1/2 study.
5117 Background: Ga-68-NGUL and Lu-177-DGUL (Pocuvotide Satetraxetan) is a novel PSMA-targeting radiopharmaceutical. This...
Tegavivint, a downstream Wnt/β-catenin inhibitor: Dose-finding results from a phase 1/2 trial in advanced hepatocellular carcinoma (aHCC).
4015 Background: Wnt/β-catenin pathway activation is a hallmark of many cancers, with Wnt pathway mutations (WPMs) present...
Trends and disparities in malignant neoplasms and Alzheimer's disease–related mortality in the United States, 1999-2023.
e23363 Background: Malignant neoplasms and Alzheimer’s disease contribute a major mortality burden in U.S. adults. The com...
Trends and expenditure of cardioprotective drugs in cancer survivors: Medical Expenditure Panel Survey (2016-2023).
e23005 Background: Cardiovascular disease (CVD) is the leading non-cancer cause of death among cancer survivors. Managing...
Beyond survival: Quality of life and symptoms burden among underprivileged breast cancer patients in Sirajganj, Bangladesh.
e24119 Background: While breast cancer survival has improved globally, post-treatment quality of life (QoL) remains inadeq...
Patterns of poly(ADP-ribose) polymerase inhibitor use and overall survival in United States veterans with prostate cancer.
e17049 Background: PARP inhibitors (PARPi) are life-prolonging therapies for men with homologous recombination repair (HRR...
Integrated reflex molecular analysis to preserve clinically actionable targets in lung cancer regardless of specimen quality and panel coverage.
e20759 Background: Comprehensive molecular profiling is essential for precision treatment of lung cancer. However, in rout...
Management strategies for PI3K/AKT inhibitor–induced hyperglycemia in HR+/HER2– metastatic breast cancer: A claims analysis.
e13048 Background: PI3K/AKT pathway inhibitors (PI3K/AKTi; alpelisib, inavolisib, and capivasertib) improve outcomes for p...
GLP-1 receptor agonists for primary prevention of breast cancer in high-risk women: A real-world analysis of efficacy and safety.
10520 Background: Therapeutic options for breast cancer (BC) prevention for high-risk women remain limited, and not all el...
Stage distribution, treatment patterns, and stage-specific survival in Merkel cell carcinoma before and after the immunotherapy era: A SEER analysis (2004–2022).
e21556 Background: Merkel cell carcinoma (MCC) survival has improved in recent years. Whether this reflects earlier diagno...
Actinic keratosis as a premalignant lesion: Systematic review and meta-analysis of topical field–directed therapy versus vehicle/placebo.
e21568 Background: Actinic keratosis represents a premalignant lesion within the field cancerization pathway and isassocia...
A multi-agent AI system integrating real-world data and competitive intelligence to generate automated trial eligibility recommendations.
e23008 Background: Designing eligibility criteria is central to clinical trial feasibility but requires laborious manual r...
Feasibility of expansion of home phlebotomy with type and screen testing for hematologic monitoring: A single-institution pilot study.
e13577 Background: Patients with hematologic malignancies require intensive supportive care, including frequent lab monito...
Diagnostic accuracy of blood-based cfDNA fragmentomic assays for lung cancer detection: A meta-analysis of clinically validated cohorts.
10577 Background: Early detection of lung cancer remains limited by suboptimal sensitivity and specificity of current scre...
Clinicopathologic characteristics of somatic <i>TP53</i> mutations in Philadelphia chromosome–negative myeloproliferative neoplasms: A systematic review and pooled analysis.
e18597 Background: TP53 mutations ( TP53 m) are uncommon in ch...
Association of socioeconomic and clinical factors with overall survival in immunotherapy-eligible stage III non-small cell lung cancer following definitive chemoradiation.
1522 Background: Use of consolidative immunotherapy (IO) for stage III non-small cell lung cancer (NSCLC) has increased si...
Clinical implications and diagnostic utility of <sup>68</sup> Gallium FAPI PET CT in patients with testicular germ cell tumors: The prospective phase Ib FAPI-TEST study.
5127 Background: The fibroblast activation protein (FAP) is overexpressed in tumor tissue by cancer associated fibroblasts...
CAR-Mix cell therapies to treat solid tumors by providing synergistic interaction between engineered macrophages and polyclonal T cells.
e14543 Background: Chimeric antigen receptor (CAR) T cells have shown remarkable success against hematologic cancers and a...
Validation of prognostic scores in Hispanic patients with advanced solid tumors enrolled in a single-center phase I clinical trial program.
1541 Background: Prognostic scores are commonly used to guide enrollment in early-phase oncology trials. Despite their wid...
Invasive-field radiotherapy plus rituximab versus rituximab alone after response to immunochemotherapy in stage III follicular lymphoma: An open-label, multicenter, randomized clinical study.
7054 Background: Stage III follicular lymphoma (FL) remains incurable with immunochemotherapy followed by rituximab mainte...
Longitudinal evaluation of a multidisciplinary lung cancer early detection program.
e20707 Background: Lung cancer remains the leading cause of cancer-related mortality in the United States and globally. Mu...
HER2-targeted tyrosine kinase inhibitors in breast cancer: Real-world analysis of gastrointestinal and musculoskeletal toxicities using the FAERS database.
1058 Background: Human Epidermal Growth Factor Receptor 2 (HER2)-targeted tyrosine kinase inhibitors (TKIs) lapatinib, ner...
Refusal of chemotherapy, surgery, and radiation in non-metastatic triple-negative breast cancer.
e12712 Background: Refusal of oncologist-recommended therapy is uncommon but clinically consequential. In triple-negative...